Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

COVID-19 Impacting Patent Litigation, From Exclusivity Forfeiture To Launch Delays

Apr 28 2020

• By Brenda Sandburg

question marks judge gavel Coronavirus Covid-19 symbolic 3d-illustration — COVID-19 Raises Numerous Questions In Biopharma Patent Litigation

Related Content

How Risky Is Amgen's At-Risk Launch Of Herceptin, Avastin Biosimilars?

Jul 22 2019

Genentech Was Too Slow In Trying To Halt Amgen's Herceptin Biosimilar Launch

Jul 26 2019

Related Companies

Genentech, Inc.

Amgen, Inc.

Additional Topics

Legal Issues Generic Drugs Biosimilars Coronavirus COVID-19 Biologics FDA Policy Intellectual Property BioPharmaceutical

More from Legal & IP

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window